Navigation Links
Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
Date:12/10/2012

Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells and Tregs (suppressors of anti-tumor activity) after total body irradiation had eliminated them. Blocking myeloid-derived suppressor cells and regulatory T-cell reconstitution improved adoptive T-cell therapy, an immunotherapy designed to suppress tumor activity.

The study appears in the December issue of The Journal of Immunology.

"Melanoma is a leading cause of cancer mortality," said Shari Pilon-Thomas, Ph.D., assistant member of the Immunology Program at Moffitt. "With few nonsurgical options for treating melanoma, immunotherapy, which focuses on the induction of immunity against cancer cells, is a promising approach. However, a major hurdle in developing effective immunotherapies is tumor-induced suppression that can limit the effectiveness of tumor-specific T-cells used in immunotherapy."

Chemotherapy or radiation can induce lymphopenia, the condition of having an abnormally low level of white blood cells. This condition is optimal for adoptive T-cell therapeutic strategies. However, after the induction of lymphopenia, suppressor populations that favor tumor progression begin reconstitution, including regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSC). According to the researchers, tumor-induced suppression can stem from quickly reconstituted Tregs and MDSC.

This knowledge led to their research question, whether blocking the reconstitution of suppressor populations - such as Tregs and myeloid derived suppressor cells - could lead to better immunotherapy in mice bearing melanoma. Mice were treated with docetaxel, a chemotherapeutic drug that targets MDSC, followed by adoptive T cell therapy. In brief, the study demonstrated that when myeloid-derived suppressor cells and Treg reconstitution are blocked, immunotherapy with adoptive T cell transfer is more effective.

"It was important to understand the role of these suppressor populations after the induction of lymphopenia so that we can design more effective immunotherapeutic treatments for melanoma aimed at achieving complete tumor regression," concluded Dr. Pilon-Thomas.


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
2. Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
3. Moffitt researcher investigates 2-drug synergy to treat drug-resistant chronic myeloid leukemia
4. Moffitt researchers identify unique immune gene signature across thousands of patients solid tumors
5. Moffitt Cancer Center researcher receives $2.1 million grant from NCI for answering Provocative Question
6. Moffitt cancer center researchers find novel predictor for MDS progression risk
7. Moffitt researchers say race affect likelihood of finding suitable stem cell donor
8. Moffitt Cancer Center researchers study childhood melanoma characteristics
9. Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
10. Review finds some evidence for chemo brain in breast cancer survivors, Moffitt Cancer Center says
11. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, a privately ... completion of the strategic executive team expansion needed to further optimize growth and ... executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... It’s that ... means many students are thinking about summer internships , which can be frustrating ... , The pros at Garden Media Group, a boutique public relations firm outside of ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Leaders Engaged ... and fatal diseases in opposition to the President’s Fiscal Year 2018 Federal ... services, and hope for the most vulnerable among us. , The proposed budget ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored to ... All events will be located in the Main West Entrance of The Boulevard ... ID event. No appointment is necessary and each child with a parent or guardian ...
(Date:3/23/2017)... ... , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a call to ... the creation of published author, Desiree M Webb, a registered nurse, minister of music, ... happily married to her husband, Paul, for over twenty-nine years. Desiree enjoys writing, ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017 The Board of Directors of ... General Meeting, which is to take place on Thursday, April 27, ... Lund, Sweden . ... Please see the attached notification, which is being announced ... NeuroVive Pharmaceutical AB (Publ) The Board Of Directors ...
(Date:3/22/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Respiratory care devices ... over the next decade to reach approximately $38.27 billion by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... , March 22, 2017 Ampio ... the development of Ampion™, a low molecular weight ... today announced that it is re-issuing its previous release ... incorporate certain disclosures that are required under the ... below are these additional disclosures along with the ...
Breaking Medicine Technology: